Q1 Earnings Estimate for Longeveron Issued By HC Wainwright

Posted by George Bondi on May 6th, 2026

Longeveron Inc. (NASDAQ:LGVN – Free Report) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Longeveron in a research report issued to clients and investors on Monday, May 4th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.23) for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.88) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.11) EPS and Q4 2027 earnings at ($0.12) EPS.

Longeveron (NASDAQ:LGVN – Get Free Report) last issued its earnings results on Tuesday, March 17th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.20. Longeveron had a negative return on equity of 199.79% and a negative net margin of 1,893.58%.The firm had revenue of $0.37 million for the quarter, compared to analyst estimates of $0.11 million.

A number of other research analysts also recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.50.

View Our Latest Research Report on Longeveron

Longeveron Trading Down 0.8%

NASDAQ LGVN opened at $0.86 on Wednesday. The company has a market capitalization of $19.92 million, a PE ratio of -0.67 and a beta of -0.31. The company has a fifty day moving average of $0.90 and a 200 day moving average of $0.72. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.33 and a quick ratio of 1.33. Longeveron has a 1 year low of $0.48 and a 1 year high of $1.80.

Institutional Investors Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent quarter. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

(Get Free Report)

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.